IGF1 and neoplasm: An important factor in support of targeting IGF-1R in ES is that EWS-FLI1 acts to suppress transcription of IGFBP3 in tumor cells, thereby resulting in higher levels of circulating IGF-1 and thus increasing activation of the IGF-1R pathway [35].